Home Infusion Therapy Market Size

Home Infusion Therapy Market Analysis

The Home Infusion Therapy Market size is estimated at USD 24.40 billion in 2024, and is expected to reach USD 33.47 billion by 2029, growing at a CAGR of 6.5% during the forecast period (2024-2029).

• As cases of COVID-19 increased in 2020, the use of alternate site solutions rose in high demand, and home and specialty infusion providers played a critical role in supporting patients. However, initiatives by key market players were expected to increase market growth. For instance, in July 2021, Eitan Medical opened a new office for the DACH region located in Germany to expand its customer base. Its Sapphire infusion system was EU MDR certified and served clinicians in hospitals and home care environments across Europe. The pump was designed to deliver a wide range of therapies for varied clinical use cases. Similarly, in January 2021, Amedisys collaborated with Option Care Health to deliver COVID-19 infusion therapy to the vulnerable population. Thus, such initiatives were expected to increase market growth.
• The growth of the market is attributed to improved patient outcomes, cost-efficiency, and patient convenience provided by home infusion therapy. The growing number of baby boomers suffering from decreased mobility profiles such as osteoarthritis, paralysis, and diabetes will boost the demand for home infusion therapy. The rising need to reduce the duration of inpatient stays is anticipated to fuel the market development. Continuous subcutaneous (SC) apomorphine infusion is an effective therapy for Parkinson's disease (PD), and various drug formulations are available for treating PD using the subcutaneous mode of delivery. Thus, with the increasing burden of PD, the demand for subcutaneous infusion therapy is rising. 
• For instance, as per the 2022 data update by the Parkinson's Foundation, approximately 90,000 people are diagnosed with PD annually in the United States, and nearly 1.2 million people in the country are estimated to be living with PD by the year 2030. In addition, as per the source above, the incidence of PD has increased in North America in the past decade, and it is estimated that men are associated with a higher incidence of PD than women.
•  As a result, techniques for administering infusion therapy at home or in other healthcare settings have been developed, which is also anticipated to support market expansion. The majority of home infusion providers still use conventional infusion pumps despite hospitals quickly adopting smart infusion pumps with fascinating features like EHR connectivity, drug libraries, and medication safety software. However, there has been a growing trend for the up-gradation of equipment owing to its increasing demand, especially in developed countries.
• Furthermore, in December 2021, Baxter International completed the acquisition of Hillrom. This acquisition will help the company broaden its geographic footprint and integrate medical device technology that will enhance patient care, lower costs, and increase workflow efficiency. Moreover, in March 2021, Terumo and Glooko, a remote patient monitoring software and mobile apps company, announced technological integration to deliver new diabetes data solutions together globally. The partnership will allow the integration of data from Terumo's diabetes care devices into Glooko'sdiasend diabetes data management platform. Similarly, in June 2021, Aducanumab (Aduhelm) received accelerated approval as a treatment for Alzheimer's disease from the United States Food and Drug Administration (FDA). This is the first FDA-approved infusion therapy to address the underlying biology of Alzheimer's disease. Thus, such acquisitions and product launches are expected to boost the growth of the market over the forecast period. However, the high cost associated with the infusion pumps may hamper business growth during the forecast period.